Sexual function preservation with common minimally invasive surgical treatments (MIST) for benign prostate hyperplasia: a narrative review of minimal invasive benign prostatic hyperplasia technology

There is a strong association between lower urinary tract symptoms/benign prostatic hyperplasia and male sexual dysfunction in terms of pathophysiology and treatmentrelated adverse event. In recent times, it has become evident that the preservation of various male sexual function domains such as erectile and ejaculatory functions are of paramount importance for many sexually active men who are contemplating benign prostatic hyperplasia (BPH) surgery. Various innovative minimally invasive benign prostatic hyperplasia technologies have been shown to improve various parameters in voiding domains while minimizing erectile dysfunction and ejaculatory disorders. The purpose of this chapter is to review three of the most promising minimally invasive endourology benign prostatic hyperplasia technology namely -Urolift®, Rezum® and Aquablation technology in terms of sexual function outcomes, including the examinations of the limitations of the interpretation of these technologies, and methodological flaws in the existing clinical trials in these approaches.